



# Publix Specialty Pharmacy #3213

## RHEUMATOLOGY

1950 Sand Lake Road, Bldg 5  
Orlando, FL 32809  
Phone: 855-797-8254  
Fax: 863-413-5723

### PATIENT INFORMATION [Attach copy of front and back of prescription insurance card(s)]

Patient's First Name: \_\_\_\_\_ Patient's Last Name: \_\_\_\_\_ Date of Birth: \_\_\_/\_\_\_/\_\_\_  Male  Female  
Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
Primary Phone Number: (\_\_\_\_) \_\_\_\_\_ Alt. Phone Number: (\_\_\_\_) \_\_\_\_\_ Caregiver name: \_\_\_\_\_

### CLINICAL INFORMATION [Attach copy of labs and clinical notes]

Diagnosis code: \_\_\_\_\_ Diagnosis:  Rheumatoid Arthritis  Ankylosing Spondylitis  Other: \_\_\_\_\_  
Treatment status:  New to therapy  Continuation of therapy, start date: \_\_\_/\_\_\_/\_\_\_ Previously denied by insurance?  No  Yes, include copy of denial letter Weight: \_\_\_\_\_ kg  lb  
Is the patient on samples?  No  Yes Height: \_\_\_\_\_ cm  in  
TB test result (within 6 months):  N/A  Negative  Positive, Date of TB test: \_\_\_/\_\_\_/\_\_\_ Allergies:  NKDA  Other: \_\_\_\_\_  
Prior therapy, treatment dates, and reason for discontinuation: \_\_\_\_\_

MEDICATION	DOSE/STRENGTH	DIRECTIONS	DISPENSE	REFILLS
<input type="checkbox"/> Actemra (tocilizumab)	<input type="checkbox"/> 162 mg/0.9 mL ACTPen <input type="checkbox"/> 162 mg/0.9 mL prefilled syringe (PFS) Patient weight: _____	<input type="checkbox"/> <100kg: Inject 162 mg SC every 2 weeks <input type="checkbox"/> ≥100kg: Inject 162 mg SC once a week	<input type="checkbox"/> 28 days <input type="checkbox"/> 84 days	_____
<input type="checkbox"/> Cimzia (certolizumab pegol)	<input type="checkbox"/> Starter Kit: 6 x 200 mg/mL PFS <input type="checkbox"/> 200 mg vial	Initial Dose: <input type="checkbox"/> Inject 400 mg SC on days 1, 15, and 29	3 doses (6 PFS/vials)	0
	<input type="checkbox"/> 200 mg/mL PFS <input type="checkbox"/> 200 mg vial	Maintenance Dose: <input type="checkbox"/> Inject 400 mg SC every 4 weeks <input type="checkbox"/> Inject 200 mg SC every 2 weeks	<input type="checkbox"/> 28 days <input type="checkbox"/> 84 days	_____
<input type="checkbox"/> Cosentyx (secukinumab)	<input type="checkbox"/> 150 mg/mL Sensoready pen <input type="checkbox"/> 150 mg/mL PFS	Initial Dose: <input type="checkbox"/> Inject 150 mg SC once a week for 5 weeks (on days 1, 8, 15, 22, and 29)	5 doses	0
		Maintenance Dose: <input type="checkbox"/> Inject 150 mg SC every 4 weeks	<input type="checkbox"/> 28 days <input type="checkbox"/> 84 days	_____
<input type="checkbox"/> Enbrel (etanercept)	<input type="checkbox"/> 50 mg/mL Mini cartridge <input type="checkbox"/> 50 mg/mL PFS	<input type="checkbox"/> Inject 50 mg SC ONCE a week <input type="checkbox"/> Inject 25 mg SC TWICE a week (3-4 days apart)	<input type="checkbox"/> 28 days <input type="checkbox"/> 84 days	_____
	<input type="checkbox"/> 50 mg/mL SureClick pen <input type="checkbox"/> 25 mg/0.5 mL PFS			
<input type="checkbox"/> Humira (adalimumab)	<input type="checkbox"/> 40 mg/0.4mL pen (citrate-free) <input type="checkbox"/> 40 mg/0.8mL pen	<input type="checkbox"/> Inject 40 mg SC every 2 weeks <input type="checkbox"/> Inject 40 mg SC once a week	<input type="checkbox"/> 28 days <input type="checkbox"/> 84 days	_____
	<input type="checkbox"/> 40 mg/0.4mL PFS (citrate-free) <input type="checkbox"/> 40 mg/0.8mL PFS			
<input type="checkbox"/> Kevzara (sarilumab)	<input type="checkbox"/> 200 mg/1.14 mL pen <input type="checkbox"/> 150 mg/1.14 mL pen	Inject 1 dose SC every 2 weeks	<input type="checkbox"/> 28 days <input type="checkbox"/> 84 days	_____
	<input type="checkbox"/> 200 mg/1.14 mL PFS <input type="checkbox"/> 150 mg/1.14 mL PFS			
<input type="checkbox"/> Olumiant (baricitinib)	2 mg tablet	Take 1 tab PO once daily with or without food	<input type="checkbox"/> 30 days <input type="checkbox"/> 90 days	_____
<input type="checkbox"/> Orencia (abatacept)	<input type="checkbox"/> 125 mg/mL ClickJect pen <input type="checkbox"/> 125 mg/mL PFS	Inject 125 mg SC once a week	<input type="checkbox"/> 28 days <input type="checkbox"/> 84 days	_____
<input type="checkbox"/> Rinvoq (upadacitinib)	15 mg tablet	Take 1 tab PO once daily with or without food	<input type="checkbox"/> 30 days <input type="checkbox"/> 90 days	_____
<input type="checkbox"/> Simponi (golimumab)	<input type="checkbox"/> 50 mg/0.5 mL SmartJect pen <input type="checkbox"/> 50 mg/0.5 mL PFS	Inject 50 mg SC every 4 weeks	<input type="checkbox"/> 28 days <input type="checkbox"/> 84 days	_____
<input type="checkbox"/> Taltz (ixekizumab)	<input type="checkbox"/> 80 mg/mL Pen <input type="checkbox"/> 80 mg/mL PFS	Initial Dose: <input type="checkbox"/> Inject 160 mg SC once on day 1	1 dose (2 pens/PFS)	0
		Maintenance Dose: <input type="checkbox"/> Inject 80 mg SC every 4 weeks starting on day 29	<input type="checkbox"/> 28 days <input type="checkbox"/> 84 days	_____
<input type="checkbox"/> Xeljanz (tofacitinib)	<input type="checkbox"/> 5 mg tablet	Take 1 tab PO BID with or without food	<input type="checkbox"/> 30 days <input type="checkbox"/> 90 days	_____
	<input type="checkbox"/> 11 mg XR tablet	Take 1 tab PO once daily with or without food		
<input type="checkbox"/> Other:	_____	_____	_____	_____

### PRESCRIBER INFORMATION [Ship to prescriber: Never Always First fill only, appointment date: \_\_\_/\_\_\_/\_\_\_ Using Cover My Meds: No Yes

Name: \_\_\_\_\_ DEA# \_\_\_\_\_ NPI # \_\_\_\_\_  
Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
Office Phone Number: (\_\_\_\_) \_\_\_\_\_ Fax Number: (\_\_\_\_) \_\_\_\_\_ Office Contact: \_\_\_\_\_

I authorize Publix Pharmacy representatives to act on behalf of the prescriber to initiate and complete the insurance prior authorization process.

Prescriber's signature: \_\_\_\_\_ Date \_\_\_\_\_  
(stamps not accepted)  Substitution allowed  Dispense as written/ Do not substitute

For states requiring hand written expressions to prevent substitution, write here:

This document, and any attachments, are intended solely for the use of the individual(s) to whom they are addressed. They may contain confidential information and/or protected health information (PHI) that is protected by law. If you believe you were not the intended recipient of this document, you are hereby notified that any review, dissemination, distribution, printing or copying of this document and/or any attachments is strictly prohibited. If you have received this transmission in error, please notify the sender immediately and destroy this document and any attachments. If you properly received this document, you should maintain its contents in confidence in accordance with applicable law.